Státní léčebné lázně Janské Lázně, státní podnik
Janske Lazne, 542 25, Czechia
NCT Number: NCT06782113
The primary objective of this clinical follow-up is to analyze data regarding the safety of the UNILEXA passive exoskeleton post-market. The secondary objective is to assess the effectiveness of the device in improving activities of daily living (ADL) through improved mobility, endurance and health-related quality of life (QoL). The aim of this study is to provide real-world evidence to support wider clinical and home use of the exoskeleton. This observational study is designed for 6 participants from a population of individuals with lower limb paralysis. The study will have a duration of 14 weeks. During this period, participants will visit Janske Lazne three times for routine measurements in a biomechanical laboratory, which will be integrated into their usual physiotherapy sessions.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Janske Lazne, 542 25, Czechia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment to the end of observation at 14 weeks
Analyze data regarding the safety of the UNILEXA exoskeleton by determining the incidence of adverse events (AEs) and adverse device effects (ADEs), such as falls, skin injuries, and other injuries, over the study period.
Time frame: From enrollment to the end of observation at 14 weeks
To assess improvements in health-related quality of life (QoL) using the WHOQOL-BREF questionnaire, a standardized questionnaire measuring QoL across four domains: physical, psychological, social relationships, and environment.
Scale range: 0-100. Interpretation: Higher scores indicate better quality of life.
Time frame: From enrollment to the end of observation at 14 weeks
To assess user satisfaction with the UNILEXA exoskeleton using the QUEST 2.0 questionnaire. This evaluates satisfaction with the device and associated services.
QUEST 2.0: A validated user satisfaction questionnaire consisting of 12 items across two subscales: device satisfaction and service satisfaction. Each item is rated on a 5-point Likert scale (1 = not satisfied at all, 5 = very satisfied).
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate the time required to walk 10 meters at a comfortable speed.
Unit of Measure: Seconds. Interpretation: Lower times indicate better functional mobility.
Time frame: From enrollment to the end of observation at 14 weeks
To assess mobility performance by measuring the time required to stand up from a chair, walk 3 meters, turn, and return to sit in the chair.
Unit of Measure: Seconds. Interpretation: Lower times indicate better functional mobility.
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate the level of physical assistance required during mobility tasks using a 6-point ordinal scale.
Scale range: 0-5, where 0 = no assistance and 5 = full physical assistance required.
Interpretation: Lower scores indicate better functional independence.
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate the perceived exertion of participants during mobility tasks using the Borg RPE scale.
Borg RPE Scale: Measures exertion on a scale from 0-10, where 0 = no exertion and 10 = maximal exertion.
Time frame: From enrollment to the end of observation at 14 weeks
To assess the pain intensity experienced by participants during mobility tasks using the Visual Analog Scale (VAS).
VAS Scale: Measures pain on a scale from 0-10, where 0 = no pain and 10 = the worst imaginable pain.
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate the cognitive and physical workload experienced by participants during mobility tasks using the NASA Task Load Index (NASA-TLX) questionnaire.
NASA-TLX: A multidimensional workload assessment tool with six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration.
Scale range: 0-20 for each subscale. Interpretation: Higher scores indicate greater workload in each category.
Time frame: From enrollment to the end of observation at 14 weeks
To assess compensatory movements by analyzing the amplitude of reflective markers placed on the acromion.
Parameters measured: Amplitude of vertical and lateral movements. Units of Measure: Millimeters (mm). Data summarization: Mean and standard deviation of marker amplitude across all trials.
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate biomechanical adaptations by measuring the amplitude of pelvic angular movements in three major planes:
Pelvic Rotation: Angular displacement in the transverse plane. Pelvic Hiking: Angular displacement in the coronal plane. Pelvic Tilting: Angular displacement in the sagittal plane. Units of Measure: Degrees (°). Data summarization: Mean and standard deviation of angular displacement for each type of movement (rotation, hiking, tilting) across all trials.
Time frame: From enrollment to the end of observation at 14 weeks
To evaluate participant progress during the training phase by recording the number of steps taken in each training session.
Unit of Measure: Number of steps. Data summarization: Total number of steps per session and average across all sessions.
Time frame: From enrollment to the end of observation at 14 weeks
To assess participant mobility during the training phase by measuring the total distance walked in each training session.
Unit of Measure: Meters (m). Data summarization: Total distance walked per session and average across all sessions.
Time frame: From enrollment to the end of observation at 14 weeks
To assess participant endurance during the training phase by recording the duration of each training session.
Unit of Measure: Minutes. Data summarization: Total duration per session and average across all sessions.
Time frame: From enrollment to the end of observation at 14 weeks
To assess physiological responses during training sessions by measuring participants' heart rates.
Unit of Measure: Beats per minute (BPM). Data summarization: Average heart rate during each session and across all sessions.
MEBSTER
Industry
Prospective Study on the Safety and Efficacy of the UNILEXA Exoskeleton for Regular Verticalization and Assisted Walking
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02632422
Central Nervous System Diseases, Nervous System Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT05664646
Autonomic Nervous System Diseases, Behavior
The Bronx, New York, United States
View Trial DetailsNCT07669181
Bone Diseases, Bone Diseases, Metabolic
Pécs, Baranya, Hungary
View Trial DetailsNCT07621900
Central Nervous System Diseases, Nervous System Diseases
Roma, RM, Italy
View Trial Details